ISSN 2736-173X
African Journal of Malaria and Tropical Diseases ISSN 4123-0981 Vol. 5 (6), pp. 341-348, June, 2017. © International Scholars Journals
Review
A study of the promising features of new Malaria vaccines
Emmanuel C. Ibezim* and Uche Odo
Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria.
*Corresponding author. E-mail: [email protected]; Tel: 08043180657.
Accepted 03 September, 2016
Abstract
Malaria is a tropical disease caused by the genus PLASMODIUM. The sexual stage of the plasmodium is carried by mosquito while the asexual stage is carried by man. Transmission from the mosquito to man is through mosquito bite. Commonly presented symptoms of malarial attack include fever, weakness, anorexia, and anaemia. Some complications such as convulsion (in children) and acute pulmonary edema are common. The conventional drugs used in malarial chemotherapy include, chloroquin, sulfadoxine/pyramethamine, quinine and primaquine. Newer drugs in use include artemisine and its derivatives (such as dihydroartemisinine, artesunate, artemether), halofantrine, atovaquine, malaria vaccines, and artemisinine combinations (such as artemether/lumenfantrine, artesunate/mefloquine). These newer drugs were developed based on some shortcomings of the conventional drugs such as drug resistance and unbearable side effects. Of all the drugs available for the first line treatment of malaria, the artemisinine combinations are the drugs of choice as they possess reduced recrudescence and relapse when given for 3 days. Some new combinations are still on trial and include fosmidomycin/clindamycin. Malaria vaccines which show some promising features are also still undergoing more trials.
Key words: malaria, chemotherapy, combination therapy, artemisinine, resistance.